Pfizer’s Muted Enthusiasm for Abrysvo Amid Stiff Competition and Strategic Shifts
January 30, 2024
At the J.P. Morgan Healthcare Conference, Pfizer’s CEO Albert Bourla labeled the launch of the RSV vaccine Abrysvo as disappointing. Despite a fourth-quarter sales increase to $515 million, Pfizer’s executives showed limited enthusiasm, avoiding projections about 2024 market share after a 35% share in 2023. Pfizer aims to boost its market presence by focusing on retail contracts and exploring new opportunities for Abrysvo, particularly in adults with medical conditions. However, Abrysvo faces stiff competition from GSK’s Arexvy, which has shown more robust sales. Pfizer remains optimistic about Abrysvo’s potential as a maternal vaccine and prioritizes oncology leadership and innovation in its 2024 strategy.
To read more, click here.
[Source: Fierce Pharma, January 30th, 2024]
